Hepatology

Papers
(The H4-Index of Hepatology is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Letter to the Editor: Association between hepatitis delta virus with liver morbidity and mortality—A systematic literature review and meta-analysis1286
Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis1125
Selective genetic inactivation of Caspase 8 in hepatocytes ameliorates progression of MASH following Jnk deficiency1068
Assessment of liver injury potential of investigational medicines in drug development639
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis458
Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition400
Cholestatic liver diseases of genetic etiology: Advances and controversies319
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial289
Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study269
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice244
Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1‐Nrf2–Dependent Manner209
Targeting hepatic serine-arginine protein kinase 2 ameliorates alcohol-associated liver disease by alternative splicing control of lipogenesis200
The Clinical Significance of Hepatic CD69+CD103+CD8+ Resident‐Memory T Cells in Autoimmune Hepatitis189
182
173
Retracted: Posttranslational regulation of polycystin‐2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage163
Mitochondrial genome diversity drives heterogeneity in hepatocellular carcinoma161
Letter to the Editor: Association of hepatitis D virus infection with liver-related outcomes157
New ubiquitomic subtypes in hepatocellular carcinoma: Insights for future therapeutic approaches151
Beyond monotherapy: Combining radiotherapy with sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus150
Second Line, Still Fine147
Reply: The causal analysis of missing confounding factors for the association between HDV and specific liver events143
The impact of LRP4 mutations on HCC recurrence and immunotherapy response141
Reply: Accurate predictor for liver disease progression in patients with DC/TBD141
Telomere dysfunction in chronic liver disease: The link from aging141
Letter to the Editor: Molecular classification based on multi-omics facilitates prognostic stratification and personalized treatment in hepatocellular carcinoma139
Retracted136
Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter study132
Letter to the Editor: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?132
Prevalence and predictors of cirrhosis and portal hypertension in the United States129
ASK1/p38 axis inhibition blocks the release of mitochondrial “danger signals” from hepatocytes and suppresses progression to cirrhosis and liver cancer126
NK-cell–elicited gasdermin-D–dependent hepatocyte pyroptosis induces neutrophil extracellular traps that facilitate HBV-related acute-on-chronic liver failure124
Single-cell immune profiling of mouse liver aging reveals Cxcl2 + macrophages recruit neutrophils to aggravate liver injury123
Sphingosine‐1‐phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy121
118
Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression118
Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release storm by targeting translation machinery116
Beyond circadian rhythms: emerging roles of ultradian rhythms in control of liver functions114
Maternal Early‐Pregnancy Glucose Concentrations and Liver Fat Among School‐Age Children113
Methyltransferase 1 is required for nonhomologous end‐joining repair and renders hepatocellular carcinoma resistant to radiotherapy111
Human-induced pluripotent stem cell–based hepatic modeling of lipid metabolism–associated TM6SF2-E167K variant110
Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma110
Obeticholic acid as second-line therapy for primary biliary cholangitis: Does target trial emulation solve the issue?110
Letter to the Editor: Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline108
Letter to the Editor: Clonally expanded CD8+ T cells in MASH—Invited guests overstaying their welcome107
Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples105
Utility of methylated DNA markers for the diagnosis of malignant biliary strictures103
Reply: Clonally expanded CD8+ T cells in MASH—Invited guests overstaying their welcome102
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study100
Aramchol improves hepatic fibrosis in metabolic dysfunction–associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology98
Management of patients with advanced HCC receiving atezolizumab/bevacizumab: Take care of cirrhosis!98
Letter to the Editor: A positive step toward cost-effective and accessible HCC detection awaits further validation97
Reply: Fiber and whole grain intakes in relation to liver cancer risk: An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies96
Hepatic encephalopathy - We are no longer those who believe that reality is what we perceive96
Reply: Liver transplantation for primary and secondary liver tumors—Patient-level meta-analyses compared to UNOS conventional indications94
Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in HSCs93
A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression92
Combined High‐Dose Continuous Renal Replacement Therapy and Plasma Exchange in the Management of Severe Multiorgan System Dysfunction Associated With Acute Liver Failure92
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease91
DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes90
A Beautiful Day in the Neighborhood: Application of Single‐Cell Transcriptomics to Unravel Liver Cell Heterogeneity in Diseased Human Livers89
MetALD: Does it require a different therapeutic option?88
Cracking HCC: Targeting diacylglycerol kinase eta to tackle therapy resistance and cancer stemness88
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death86
Liver transplantation for alcohol-associated liver disease86
A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases85
Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling84
Uncovering epigenetic heterogeneity in HCC83
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?82
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates82
Pharmaceutical SH2 domain–containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity81
Late-Breaking Abstracts81
Nutritional aspects of prehabilitation in adults with cirrhosis awaiting liver transplant80
Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?80
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis80
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice79
Back to phosphodiesterase inhibitors for liver disease: are we ready for clinical trials?78
0.073766946792603